Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, single arm, multi-center phase II clinical trial. The primary
study objective is to evaluate the safety of tegafur gimeracil oteracil potassium capsule
plus oxaliplatin and Camrelizumab as adjuvant therapy in stage III gastric cancer, including
the incidences and types of adverse events. The secondary study objective is to observe and
evaluate the disease-free survival (DFS), overall survival (OS) and treatment completion
rate.